ISBN 10: 1933722487 / ISBN 13: 9781933722481
Gebraucht / Anzahl: 0
Bei weiteren Verkäufern erhältlich
Alle  Exemplare dieses Buches anzeigen

Über dieses Buch

Leider ist dieses Exemplar nicht mehr verfügbar. Wir haben Ihnen weitere Exemplare dieses Titels unten aufgelistet.


Brand New, Unread Copy in Perfect Condition. A+ Customer Service!. Buchnummer des Verkäufers

Über diesen Titel:

Bewertung (bereitgestellt von GoodReads):
0 durchschnittlich
(0 Bewertungen)


This book is written with all stakeholders in mind; the regulatory agencies and the healthcare industry, including their suppliers. As the process of adoption, implementation and interpretation of Quality by Design is currently the key driver to help industry bring products to market faster and at the same time provide maximum assurance of product quality. Though pharmaceutical companies need to abide the law and therefore comply with the applicable laws, rules and regulations, their goal must be to be profitable. A business case must therefore not only outline how compliance can be achieved, maintained and improved, but also how this will result in a positive financial impact. Global subject matter experts offer invaluable information that will guide companies who wish to:

  • Proactively address regulatory trends
  • Reduce or eliminate the number of reworked batches
  • Achieve better manufacturability and process robustness
  • Drastically reduce recalls
  • Achieve leadership in the industry

  • Cutting the cost of drug development is an overarching goal for the entire pharmaceutical industry. Any program that promises to make a significant contribution to it will certainly be welcome. Drug regulatory authorities almost anywhere base their decisions on three criteria: quality, efficacy and safety. They take no account of the actual or potential cost of the product to the company. Consequently, in addition for a need to be compliant with regulatory requirements there is an equal imperative for industry to examine the value for money they get from process development and acquisition of knowledge.

    Über den Autor:

    Siegfried Schmitt, Principal Consultant, joined PAREXEL Consulting in 2007. He provides consulting services to the medical device and pharmaceutical industry on all aspects of regulatory compliance, particularly the design and implementation of Quality Management Systems and Competitive Compliance. Dr Schmitt`s areas of expertise include all aspects of quality and compliance for the product lifecycle, from R&D, to clinical trials, to commercialisation and post-marketing studies. He has previously held positions in industry as Senior Production Chemist with Roche and global Quality Director with GE Healthcare, and as Validation Manager with Raytheon and Senior Lead Consultant with ABB. Dr Schmitt is an active member of various industry associations, including DIA, PDA, RAPS and ISPE, conference presenter and organiser of international events. He is also an accomplished author and editor, having won the coveted `distinguished PDA author / editor award' for 2008. Dr Schmitt is a Chemist by background and holds Chartered Chemist and Chartered Scientist status. He is fluent in English and German.

    „Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.

    Bibliografische Details

    Zustand: New

    Beste Suchergebnisse bei AbeBooks


    Schmitt, Siegfried Ed
    Verlag: Parenteral Drug Association (2011)
    ISBN 10: 1933722487 ISBN 13: 9781933722481
    Neu Hardcover Anzahl: 1
    Revaluation Books
    (Exeter, Vereinigtes Königreich)

    Buchbeschreibung Parenteral Drug Association, 2011. Hardcover. Buchzustand: Brand New. 1st edition. 338 pages. 9.29x6.14x0.94 inches. In Stock. Buchnummer des Verkäufers zk1933722487

    Weitere Informationen zu diesem Verkäufer | Frage an den Anbieter

    Neu kaufen
    EUR 492,94
    Währung umrechnen

    In den Warenkorb

    Versand: EUR 6,92
    Von Vereinigtes Königreich nach USA
    Versandziele, Kosten & Dauer